Melphalan (Alkeran)

Melphalan, marketed under the brand name Alkeran and also known as L-PAM (L-phenylalanine mustard), is a nitrogen mustard-type alkylating agent used in feline oncology primarily for the treatment of multiple myeloma and related plasma cell neoplasms. This chemotherapy medication has been utilized in human and veterinary medicine for decades and represents the standard first-line treatment for multiple myeloma in cats. While multiple myeloma is relatively rare in cats, accounting for less than 1% of feline hematopoietic neoplasms, melphalan provides affected patients with a meaningful therapeutic option that can extend quality survival time.

The mechanism of action of melphalan involves the formation of cross-links between DNA strands, which prevents cancer cells from successfully replicating their genetic material. As a bifunctional alkylating agent, melphalan binds to DNA primarily at the N7 position of guanine, creating interstrand cross-links that disrupt the double helix structure. This damage triggers programmed cell death (apoptosis) in affected cells. Melphalan is not cell-cycle phase specific, meaning it can damage DNA in cancer cells regardless of their stage in the division cycle, though rapidly dividing cells are generally more susceptible.

Melphalan is available in oral tablet form and as an injectable solution, though oral administration represents the most common route for feline patients. The drug demonstrates high oral bioavailability, meaning it is well absorbed from the gastrointestinal tract when given by mouth. Tablets are available in 2 mg strength, allowing for precise dosing adjustments based on the cat's size and response to therapy. Injectable melphalan may be used in hospital settings when faster initial response is needed or when oral administration is not feasible.

Treatment with melphalan in cats typically involves combination therapy with corticosteroids such as prednisolone, following protocols adapted from human and canine medicine. This combined approach has demonstrated effectiveness in managing feline multiple myeloma, with responsive cats achieving clinical improvement and extended survival times. However, cats appear to be more susceptible to melphalan-induced myelosuppression than dogs, requiring careful monitoring and potentially modified dosing protocols. Working with a veterinary oncologist ensures appropriate treatment planning and monitoring for cats receiving this important anticancer medication.

Multiple myeloma represents the primary indication for melphalan in feline medicine, where the drug serves as the standard first-line chemotherapy treatment. Multiple myeloma is a cancer of plasma cells (antibody-producing white blood cells) that typically develops in the bone marrow and produces excessive amounts of abnormal immunoglobulins. While this cancer is uncommon in cats, affecting mainly older individuals without clear breed or sex predisposition, it causes significant morbidity including bone destruction, anemia, kidney damage, and increased susceptibility to infections. Melphalan combined with prednisolone provides the most established treatment approach for this condition.

Studies evaluating melphalan and prednisolone combination therapy in cats with multiple myeloma have demonstrated meaningful clinical benefit. Research indicates that approximately 63% of treated cats respond to chemotherapy, with response appearing more likely in cats with less aggressive disease. Cats achieving response to therapy show clinical improvement including resolution of disease-related symptoms, reduction in abnormal protein levels, and improved quality of life. Survival times in responding cats can extend to 15-24 months, representing significant extensions compared to untreated disease.

Beyond multiple myeloma, melphalan appears in rescue chemotherapy protocols for cats with relapsed or resistant lymphoma. The DMAC protocol (dexamethasone, melphalan, actinomycin-D, and cytarabine) and MOMP protocol (mechlorethamine, vincristine, melphalan, and prednisolone) represent examples of rescue regimens incorporating melphalan for cats that have failed first-line treatments. While response rates to rescue protocols are generally lower than initial therapy, these options provide additional therapeutic possibilities for cats with limited treatment alternatives.

Resistant leukemia in cats represents another potential indication for melphalan therapy, though this use is less common and less well-documented than treatment for myeloma. The drug's mechanism of action against rapidly dividing cells provides theoretical benefit against leukemic cells, and melphalan may be considered when standard leukemia treatments have proven ineffective. Individual treatment decisions in these situations require careful evaluation by veterinary oncologists familiar with the limited evidence supporting such use.

Melphalan selection over alternative therapies depends on multiple factors including the specific diagnosis, disease characteristics, the cat's overall health status, and practical considerations. For multiple myeloma, melphalan remains the preferred agent based on established efficacy. For rescue lymphoma protocols, the choice between melphalan-containing regimens and alternatives depends on previous treatments received, specific tumor characteristics, and individual patient factors that the veterinary oncologist evaluates when designing treatment approaches.

The dosing of melphalan in cats differs significantly from protocols used in dogs due to the increased susceptibility of feline patients to myelosuppression. For multiple myeloma treatment, the standard feline protocol involves melphalan at 0.1 mg/kg (or approximately 0.5 mg total dose regardless of weight in typical-sized cats) administered orally once daily for 10 to 14 days as an induction phase. Following induction, the drug transitions to every-other-day administration until clinical improvement or bone marrow suppression develops. This approach recognizes that cats require more conservative dosing than dogs to avoid dangerous toxicity.

Maintenance therapy following successful induction typically involves melphalan at 0.5 mg (one-quarter of a 2 mg tablet) given once weekly. This reduced frequency aims to maintain disease control while minimizing cumulative bone marrow toxicity. Some cats may require even less frequent administration, with dosing intervals extending to every two to three weeks based on blood count monitoring. The veterinary oncologist adjusts maintenance dosing based on individual response and tolerability, recognizing that optimal protocols may vary between patients.

Melphalan is almost always administered in combination with corticosteroids for multiple myeloma treatment. Prednisolone is typically given concurrently at 0.5 mg/kg orally once daily. The combination of melphalan and prednisolone provides synergistic anticancer effects, with the corticosteroid contributing both direct antitumor activity and supportive benefits including appetite stimulation and anti-inflammatory effects. This combination approach follows established protocols from human and canine oncology adapted for feline use.

Administration of oral melphalan should follow veterinary instructions precisely, as the narrow therapeutic window leaves little margin for error. Studies have shown that melphalan absorption can vary, and some veterinarians recommend giving the medication on an empty stomach for more consistent absorption, while others allow administration with food to reduce gastrointestinal upset. Pet owners should follow their specific veterinarian's instructions. Tablets should not be crushed or split unless specifically instructed, and gloves should be worn when handling the medication.

If leukopenia (low white blood cell count) develops during treatment, melphalan administration should be discontinued while prednisolone continues. Once white blood cell counts return to acceptable levels, melphalan can be restarted at a maintenance dose of one-quarter tablet weekly. Some cats experience repeated episodes of myelosuppression requiring further dose modifications or extended intervals between treatments. The veterinary oncologist monitors blood counts regularly and adjusts the protocol as needed to balance disease control with safety.

Treatment duration with melphalan for multiple myeloma continues indefinitely as long as the cat remains in remission with acceptable quality of life. Unlike some chemotherapy protocols with defined endpoints, myeloma management typically requires ongoing therapy to maintain disease control. Discontinuing treatment generally leads to disease relapse. Regular monitoring appointments allow assessment of continued response and early detection of any toxicity requiring protocol modification.

Bone marrow suppression represents the most significant side effect of melphalan in cats, with feline patients demonstrating greater susceptibility to this toxicity compared to dogs. Myelosuppression can manifest as neutropenia (decreased white blood cells), thrombocytopenia (decreased platelets), and anemia (decreased red blood cells). Studies of cats with multiple myeloma treated with melphalan and prednisolone report that neutropenia commonly develops, typically appearing within one to four weeks after starting treatment. This side effect necessitates regular blood count monitoring throughout therapy.

The consequences of myelosuppression can be serious if not detected and managed appropriately. Neutropenic cats face increased risk of infections that may become life-threatening, as their immune systems cannot mount adequate responses to bacterial, viral, or fungal pathogens. Signs of infection such as fever, lethargy, loss of appetite, or respiratory symptoms require immediate veterinary attention. Thrombocytopenia increases bleeding risk, with affected cats potentially developing spontaneous bruising, prolonged bleeding from minor injuries, or internal hemorrhage. Anemia causes weakness, lethargy, pale gums, and decreased exercise tolerance.

Gastrointestinal side effects including nausea, vomiting, diarrhea, and decreased appetite can occur with melphalan treatment, though these effects are generally less common than bone marrow suppression. When gastrointestinal symptoms develop, they are usually mild to moderate in severity. Anti-nausea medications and appetite stimulants can help manage these symptoms. Severe or persistent gastrointestinal upset warrants veterinary evaluation to rule out other causes and adjust supportive care as needed.

Oral ulceration has been reported as a potential side effect of melphalan in some species, though documentation in cats is limited. Pet owners should monitor their cats for signs of mouth discomfort such as reluctance to eat, drooling, or pawing at the mouth. Any sores or inflammation visible in the mouth should be reported to the veterinary oncologist.

Long-term melphalan use carries theoretical risks of secondary malignancies and cumulative organ damage, as described in human patients. However, given typical treatment durations and life expectancies in feline cancer patients, these concerns are less clinically relevant than in human oncology. The primary focus remains on managing the immediate and short-term side effects through appropriate monitoring and dose adjustments. Pet owners should understand that the goal of chemotherapy in cats is quality of life maintenance, and protocols are designed to minimize side effects while providing disease control.

Melphalan should not be administered to cats with known hypersensitivity or previous severe allergic reactions to the drug or related nitrogen mustard compounds. While true allergic reactions to melphalan are uncommon, any cat that has experienced anaphylaxis or serious hypersensitivity during previous treatment should not receive the medication again. Pet owners should provide complete medical histories to the veterinary oncologist, including information about any prior adverse reactions to medications.

Pre-existing bone marrow suppression represents a significant contraindication to melphalan administration. Cats with neutropenia, thrombocytopenia, or anemia from any cause should not receive melphalan until blood counts recover to acceptable levels. This includes cats with bone marrow suppression from multiple myeloma itself, previous chemotherapy, other medications, or concurrent diseases affecting bone marrow function. Baseline complete blood counts are essential before initiating therapy, with treatment delayed until values fall within safe ranges.

Severe kidney disease requires careful consideration before starting melphalan therapy in cats. Multiple myeloma frequently causes kidney damage through various mechanisms including protein deposition and hypercalcemia, meaning many cats presenting with this diagnosis already have compromised renal function. While melphalan is primarily metabolized and does not rely heavily on renal excretion, the overall health implications of severe kidney disease may affect treatment decisions and require modified protocols or enhanced monitoring.

Pregnancy is an absolute contraindication to melphalan use due to the drug's teratogenic effects and embryotoxicity. Melphalan should not be administered to pregnant cats, as it will cause fetal abnormalities or death. Nursing queens should not receive melphalan, as the drug may pass into milk and harm nursing kittens. Cats intended for breeding should not receive melphalan treatment, as the drug can cause permanent damage to reproductive function in both males and females.

Active serious infections generally preclude melphalan administration until the infection is controlled. Starting immunosuppressive chemotherapy in the presence of active infection risks overwhelming sepsis as the immune system becomes further compromised. Cats should be evaluated for signs of infection before each treatment, and therapy should be delayed if infection is suspected or confirmed. The veterinary oncologist weighs the risks of treatment delay against infection risk when making these decisions for individual patients.

Complete disclosure of all medications, supplements, and over-the-counter products a cat receives is essential before initiating melphalan therapy. While specific drug interaction studies with melphalan in cats are limited, the potential for clinically significant interactions exists based on the drug's mechanism of action and metabolism. The veterinary oncologist needs comprehensive medication information to anticipate potential problems and adjust treatment plans accordingly.

Concurrent use of other myelosuppressive drugs with melphalan significantly increases the risk of severe bone marrow suppression. This includes other chemotherapy agents, which may be used intentionally in combination protocols but require careful dose adjustments and enhanced monitoring. Medications such as chloramphenicol and other drugs known to suppress bone marrow function should be avoided or used with extreme caution in cats receiving melphalan. The cumulative effect on blood cell production can lead to life-threatening neutropenia, anemia, or thrombocytopenia.

Immunosuppressive medications combined with melphalan compound the risk of serious infections. While prednisolone is routinely combined with melphalan for multiple myeloma treatment, this combination is managed through appropriate monitoring. Additional immunosuppressive drugs such as cyclosporine, tacrolimus, or other agents used for immune-mediated conditions may pose unacceptable risks when combined with melphalan chemotherapy. The veterinary oncologist evaluates the overall immunosuppression burden when planning treatment.

Live virus vaccines should not be administered to cats receiving melphalan therapy, as the immunosuppressed state may allow vaccine strains to cause disease. Vaccination schedules should be coordinated with the veterinary oncology team, with live vaccines postponed until treatment is complete and immune function has recovered. Killed vaccines may be given if essential but may produce suboptimal responses in immunosuppressed patients.

Nephrotoxic drugs require careful consideration in cats receiving melphalan, particularly given the frequency of kidney involvement in multiple myeloma. Nonsteroidal anti-inflammatory drugs, aminoglycoside antibiotics, and other potentially nephrotoxic medications should be used cautiously, if at all, in cats undergoing melphalan treatment. Maintaining adequate hydration and monitoring kidney function helps protect against cumulative renal damage. Pet owners should inform their veterinarian of all medications before any are added to or removed from their cat's treatment regimen.

Melphalan is classified as a hazardous drug requiring careful handling by pet owners and veterinary staff to prevent accidental exposure and potential health effects. Pet owners should wear disposable gloves whenever handling melphalan tablets and should never crush, break, or split tablets unless specifically instructed by the veterinarian. If accidental skin contact occurs, the area should be washed immediately with soap and water. Pregnant women, nursing mothers, individuals trying to conceive, and immunocompromised persons should not handle melphalan or clean litter boxes of treated cats.

Body fluid precautions apply for several days following melphalan administration. The cat's urine, feces, vomit, and other body fluids may contain the drug or its metabolites. Pet owners should wear gloves when cleaning litter boxes and handling any accidents during this period. Waste should be sealed in plastic bags before disposal with regular trash. Multi-cat households should provide separate litter boxes for treated cats when possible. Thorough handwashing after any potential exposure, even with glove use, provides additional protection.

Regular and consistent blood count monitoring is absolutely essential throughout melphalan treatment due to the significant risk of myelosuppression in cats. Complete blood counts should be performed before starting therapy, weekly during the induction phase, and at appropriate intervals during maintenance therapy. If white blood cell counts drop below safe thresholds, melphalan must be discontinued until recovery occurs. The veterinary oncologist establishes specific monitoring schedules and threshold values for treatment decisions based on individual patient factors.

Pet owners must recognize warning signs requiring immediate veterinary attention during melphalan therapy. Fever may indicate infection in a neutropenic cat and requires urgent evaluation and treatment. Other concerning signs include lethargy, weakness, loss of appetite, bleeding or bruising, pale gums, difficulty breathing, and collapse. Cats receiving chemotherapy have reduced ability to fight infections, making prompt recognition and treatment of illness essential for survival.

Geriatric cats, which represent the majority of feline multiple myeloma patients, require careful pre-treatment evaluation and potentially modified protocols. Older cats commonly have concurrent health conditions including kidney disease, heart disease, or endocrine disorders that affect treatment planning. Comprehensive initial assessment establishes baseline organ function and identifies conditions requiring management alongside cancer treatment. The veterinary oncologist considers all health factors when designing individualized protocols that balance efficacy with safety for each patient.

Melphalan tablets should be stored at room temperature between 68°F and 77°F (20°C and 25°C) in a tightly sealed container protected from light and moisture. The medication should be kept in its original pharmacy container, which is designed to maintain stability and protect against environmental exposure. Storage locations should be secure, away from children and pets, and separate from food preparation areas. Avoid storing melphalan near heat sources, in direct sunlight, or in humid environments such as bathrooms.

The stability of melphalan can be affected by storage conditions, and degraded medication may be less effective or potentially more toxic. Pet owners should check expiration dates before each use and should not administer medication that has expired or shows signs of deterioration such as color changes or unusual odor. If there is any question about medication integrity, pet owners should consult their veterinarian or pharmacist before use.

Safe handling of melphalan requires consistent protective measures due to its classification as a hazardous substance capable of causing harm through skin contact, inhalation, or accidental ingestion. Always wear disposable gloves when handling tablets, removing them from containers, or cleaning up any spilled medication. Gloves should be discarded after each use. Do not handle tablets with bare hands. Wash hands thoroughly after removing gloves and after any potential contact with the medication.

If a tablet is accidentally dropped, pick it up using gloves and assess for damage before returning to the container or disposing if compromised. Do not crush, break, or split tablets unless specifically instructed, as this releases powdered drug posing inhalation and contact hazards. If tablet division is required for dosing, follow veterinary instructions precisely and use appropriate protective equipment.

Proper disposal of unused or expired melphalan requires special handling due to environmental and safety concerns. Chemotherapy drugs should never be flushed down toilets or drains or placed in regular household garbage. Drug take-back programs offered through veterinary clinics, pharmacies, or community organizations provide the safest disposal method. The dispensing veterinary clinic may accept unused medication for proper disposal. If no take-back option is available, contact local hazardous waste facilities for guidance. Never throw melphalan in regular trash where it could be accessed by children, pets, or sanitation workers.

Melphalan can be administered to cats of all breeds without documented breed-specific variations in drug response or toxicity. Unlike certain medications where genetic variations between breeds affect metabolism or sensitivity, melphalan appears to work similarly across the diverse feline population. Veterinary oncologists apply standard dosing protocols based on body weight rather than breed, with adjustments made for individual patient factors such as age, organ function, and disease status.

Multiple myeloma, the primary indication for melphalan in cats, does not appear to have significant breed predispositions. This cancer affects cats of various breeds as well as domestic shorthairs and longhairs, typically developing in middle-aged to older individuals. The lack of clear breed predisposition means that melphalan is used across a broad population of feline patients without expectations of breed-related response variations.

Body size differences between cat breeds influence total melphalan doses administered, though the dose per kilogram of body weight remains consistent. Larger breeds require higher absolute doses to achieve appropriate drug exposure, while smaller cats receive less total medication. Accurate body weight measurement at each treatment allows precise dose calculation, which is particularly important given melphalan's narrow therapeutic window and cats' sensitivity to myelosuppression.

Age-related considerations typically outweigh breed factors in melphalan treatment planning. Most cats with multiple myeloma are middle-aged to elderly, with disease occurring without clear age predilection though generally affecting mature adults. Older cats of any breed may have age-related changes in organ function that affect drug handling and toxicity risk. Pre-treatment evaluation of kidney and liver function helps identify cats requiring modified approaches. The presence of concurrent age-related diseases such as hyperthyroidism, diabetes, or heart disease may influence overall treatment decisions regardless of breed.

Purebred cats with known breed-specific health tendencies may require additional consideration during cancer treatment, though not specifically related to melphalan itself. For example, breeds prone to heart disease should have cardiac evaluation before treatment, and those predisposed to kidney disease may require enhanced renal monitoring. These considerations reflect overall patient management rather than breed-specific melphalan effects.

Within the alkylating agent drug class, several alternatives to melphalan exist for various feline cancer treatment applications, though melphalan remains the preferred agent for multiple myeloma. Chlorambucil (Leukeran) represents another oral alkylating agent used extensively in feline oncology, particularly for low-grade lymphoma and chronic lymphocytic leukemia. Chlorambucil generally causes less myelosuppression than melphalan and may be substituted in some protocols where bone marrow tolerance is a concern.

Cyclophosphamide, the most widely used alkylating agent in veterinary oncology, may be administered intravenously in combination with oral melphalan to achieve faster initial response in severely affected multiple myeloma patients. This combination approach borrows from human oncology protocols and may be considered for cats with aggressive disease requiring rapid intervention. However, the combination increases myelosuppression risk and requires enhanced monitoring.

Lomustine (CCNU) represents another alkylating agent with documented activity against feline lymphoma and mast cell tumors. While not typically used for multiple myeloma, lomustine may appear in rescue protocols for cats with relapsed disease. The drug's ability to penetrate the central nervous system provides advantages for certain tumor types but is not specifically relevant to myeloma treatment.

Prednisolone or prednisone forms an essential component of melphalan-based protocols rather than an alternative. The combination of melphalan and corticosteroids provides synergistic antitumor effects for multiple myeloma, with the corticosteroid contributing direct plasma cell toxicity along with supportive benefits. Corticosteroid monotherapy may produce temporary responses in myeloma patients but is generally inferior to combination therapy.

Supportive medications play important roles alongside melphalan therapy. Anti-nausea drugs help manage gastrointestinal side effects when they occur. Antibiotics may be prescribed prophylactically or therapeutically for cats at risk of or experiencing infection during neutropenic periods. Pain management may be necessary for cats with bone involvement from myeloma. Bisphosphonates are sometimes used to address myeloma-related bone disease. The comprehensive treatment approach extends beyond chemotherapy alone to address all aspects of the patient's condition. Pet owners should never add medications or supplements without veterinary guidance, as interactions could affect treatment safety and efficacy.